摘要 |
This invention provides caspase inhibitors of formula I: wherein Z is oxygen or sulfur; R<SUP>1 </SUP>is hydrogen, -CHN<SUB>2</SUB>, R, CH<SUB>2</SUB>OR, CH<SUB>2</SUB>SR, or -CH<SUB>2</SUB>Y; <img id="CUSTOM-CHARACTER-00001" he="2.79mm" wi="6.35mm" file="US07442790-20081028-P00001.TIF" alt="custom character" img-content="character" img-format="tif"/> between R<SUP>3 </SUP>and R<SUP>4 </SUP>represents a single or double bond; Y is an electronegative leaving group; R<SUP>2 </SUP>is CO<SUB>2</SUB>H, CH<SUB>2</SUB>CO<SUB>2</SUB>H, or esters, amides or isosteres thereof; R<SUP>3</SUP>is a group capable of fitting into the S2 subsite of a caspase enzyme; R<SUP>4 </SUP>is a hydrogen or C<SUB>1-6 </SUB>alkyl or R<SUP>3 </SUP>and R<SUP>4 </SUP>taken together form a ring; Ring A and Ring B are each heterocyclic rings, and R and R<SUP>5 </SUP>are as described in the specification. The compounds are effective inhibitors of apoptosis and IL-1beta secretion.
|